Literature DB >> 11375299

The CYP3A4*3 allele: is it really rare?

R H van Schaik1, S N de Wildt, R Brosens, M van Fessem, J N van den Anker, J Lindemans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11375299

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  15 in total

Review 1.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 2.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

3.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Robin J Leach; Teresa L Johnson-Pais; Ann W Hsing; Ashraful Hoque; Howard L Parnes; Jeannette M Schenk; Catherine M Tangen; Ian M Thompson; Juergen K V Reichardt; William D Figg
Journal:  Cancer       Date:  2016-05-10       Impact factor: 6.860

Review 4.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

5.  Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

Authors:  Laura Magliulo; Marja-Liisa Dahl; Grazia Lombardi; Silvia Fallarini; Laura Maria Villa; Aldo Biolcati; Maria Gabriella Scordo
Journal:  Eur J Clin Pharmacol       Date:  2010-10-08       Impact factor: 2.953

6.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

7.  Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.

Authors:  Lauren L Richards-Waugh; Donald A Primerano; Yulia Dementieva; James C Kraner; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2014-10       Impact factor: 3.367

8.  Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.

Authors:  Mari Jiko; Ikuko Yano; Eriko Sato; Kazushige Takahashi; Hideyuki Motohashi; Satohiro Masuda; Masahiro Okuda; Noriyuki Ito; Eijiro Nakamura; Takehiko Segawa; Toshiyuki Kamoto; Osamu Ogawa; Ken-Ichi Inui
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

Review 9.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

10.  Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug.

Authors:  Qian Li; Yue-E Wu; Kai Wang; Hai-Yan Shi; Yue Zhou; Yi Zheng; Guo-Xiang Hao; Yi-Lei Yang; Le-Qun Su; Wen-Qi Wang; Xin-Mei Yang; Wei Zhao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.